NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of 2026 after market close
NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in the upcoming 2026 Cantor Global
NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in the upcoming Wells Fargo 21st
--Q2 2026 total revenue of $22.8 million, including $22.5 million in RNS revenue representing 21% growth--
--Raises full year 2026 total revenue guidance to $99.5 million to $101.5 million, which assumes 21% to 23%
-- Company received communication from FDA indicating that the PMA Supplement for idiopathic generalized epilepsy is not approvable in its current form and that additional clinical evidence from the NAUTILUS trial and
--ASSFN program to feature thalamic neuromodulation, NAUTILUS data in idiopathic generalized epilepsy, and emerging applications for broader epilepsy populations--
--NeuroPace to engage neurosurgeon community through
-- First in a suite of planned NeuroPace AI tools designed to deliver deeper data insights, support clinical outcomes and further enhance efficiency of RNS therapy --
NeuroPace, Inc. (NASDAQ:NPCE), a medical device
--Total revenue of $22.1 million--
-- Raises full year 2026 guidance to $99 million to $101 million, up from $98 million to $100 million previously--
--Assumes 21% to 23% growth in core RNS® revenue from
NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of 2026 after market close
— Published 3-year Post-Approval Study results show 82% median seizure reduction in drug-resistant focal epilepsy —
— American Academy of Neurology (AAN) presentation featured 12- and 18-month NAUTILUS data, the first
NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 25th Annual Needham Virtual
NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the Leerink 2026 Global Healthcare
NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter of 2025 after market
--Revenue expected to be approximately $100.0 million in FY 2025, representing growth of 25%--
--Revenue expected to be approximately $26.6 million in Q4 2025, representing growth of 24%--
-- 2026 guidance assumes
